RecruitingPhase 2NCT07616128

Study of EVO756 in Adults With Migraine

A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults

Sponsor

Evommune, Inc.

Enrollment

330 participants

Start Date

Jul 29, 2026

Study Type

INTERVENTIONAL

Conditions

Migraine

Summary

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

Eligibility

Min Age: 18 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EVO756, Dose 1, a drug called EVO756, Dose 2, and others for people with migraine. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years to 64 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEVO756, Dose 1

Orally administered EVO756, Dose 1 (Daily)

DRUGEVO756, Dose 2

Orally administered EVO756, Dose 2 (Daily)

DRUGPlacebo

Placebo Control (Daily)

Locations(26)

Trialsphere Corp

Chandler, Arizona, United States

Buena Park Research Center

Buena Park, California, United States

Neuro Pain Research Center

Fresno, California, United States

CA Medical Clinic for Headache

Los Angeles, California, United States

Diablo Clinical Research dba Flourish Research

Walnut Creek, California, United States

New England Institute for Neurology and Headache

Stamford, Connecticut, United States

Clinical Neuroscience Solutions, Inc.

Jacksonville, Florida, United States

Apple Medical Research Group, Inc

Miami, Florida, United States

Blessed Healthcase & Research

Miami, Florida, United States

Florida Research Center, Inc.

Miami, Florida, United States

Clinical Neuroscience Solutions, Inc.

Orlando, Florida, United States

Vantage Clinical Trials

Tampa, Florida, United States

Premiere Research Institute at Palm Beach Neurology

West Palm Beach, Florida, United States

Accel Research Site-Decatur-Alcanza

Decatur, Georgia, United States

Mass Institute of Clinical Research

Westborough, Massachusetts, United States

Michigan Headache and Neurological Institute

Ann Arbor, Michigan, United States

Quest Research Institute-Alcanza

Farmington Hills, Michigan, United States

Bio Behavoural health

Toms River, New Jersey, United States

Clinosis - Dent Neurologic Instite

Amherst, New York, United States

Asheville Neurology Specialists, Pa

Asheville, North Carolina, United States

Eximia Research NC

Raleigh, North Carolina, United States

Clinical Trials of South Carolina

Charleston, South Carolina, United States

FutureSearch Trials of Neurology

Austin, Texas, United States

FutureSearch Trials of Dallas

Dallas, Texas, United States

SFF Medical Research Group LLC

Houston, Texas, United States

Vaught Neurological Services

Crab Orchard, West Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07616128

Related Trials

Tai Chi and Acupuncture on Migraine Attack Prevention and Brain White Matter Changes

NCT06967909

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302129 locations

Objectively Diagnose and Monitor Treatment of Light Sensitivity

NCT036946261 location

Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine

NCT072230081 location

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

NCT076466136 locations